{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-256325","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.687164+00:00","generated_at":"2026-05-17T01:50:00.489860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OPKO Q3 net income $21.6M; Regeneron collaboration with $1B+ potential; sells BioReference oncology to Labcorp for $225M","bullets":["Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.","Entered multi-program Regeneron collaboration for multispecific antibodies; upfront plus milestones >$200M per program, total potential >$1B.","Completed sale of BioReference oncology assets to Labcorp for $225M ($192.5M cash + $32.5M earnout); net gain of $101.6M recorded.","Pharmaceuticals revenue $37.7M (Rayaldee $7.5M, up 29%); diagnostics revenue $95.2M, down due to prior-year asset sales.","Cash, cash equivalents and restricted cash $428.9M at Sep 30, 2025; $73.8M used in share repurchase program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-256325","json":"https://secwatch.observer/filing/0001193125-25-256325.json","markdown":"https://secwatch.observer/filing/0001193125-25-256325.md","text":"https://secwatch.observer/filing/0001193125-25-256325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000119312525256325/0001193125-25-256325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000119312525256325/opk-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:50:00.489860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}